A recent corporate slide deck from Zentalis^1 provides helpful information regarding the current high unmet needs in treating ovarian cancer:
Almost 50,000 newly diagnosed ovarian cancer patients annually (FIG. 1 📷)
High unmet need for better therapies/cures for ovarian cancer
Over 32,000 annual ovarian cancer deaths (FIG. 1 📷)
Current treatment paradigm is complex (FIG. 2 📷)
BRCA/homologous repair deficient (HRD) biomarkers are helpful for identifying patients most likely to benefit from PARP inhibitors
Current therapies are not cures
There remains a large unmet need in platinum resistant ovarian cancer
>50,000 treatable patients in the U.S. and EU5 in the 1st line maintenance setting
> 40,000 treatable patients in the in the U.S. and EU5 in the platinum resistant setting
^1 About Zentalis
Zentalis (ZNTL) is a NY headquartered pharma company with a research hub in San Diego whose lead asset, ZN-c3, is an oral, small molecule Wee-1 inhibitor that it is developing initially for ovarian cancer. The molecule is active, and being developed by ZNTL against a variety of cancer. ZN-c3 targets WEE1 and is directed to accelerating DNA damage and cell death in actively dividing cancer cells (FIG. 3 📷).
This article is not legal or investment advice.
Posted 1/17/24 EJV